Literature DB >> 3290346

Response of tumours to hyperglycaemia: characterization, significance and role in hyperthermia.

K A Ward1, R K Jain.   

Abstract

The response of both neoplastic and surrounding normal tissue to hyperthermia is influenced by a number of physical, physiological, biological and immunological factors. Two physiological factors that play an important role are blood flow and pH. Temperature distributions within neoplastic and surrounding normal tissue during hyperthermia are influenced by convective heat transfer between the blood and tissue bed. A number of in vitro studies have illustrated that lowering media pH sensitizes cells to hyperthermia. It has been suggested that pharmacological agents could be used in conjunction with hyperthermia treatment to improve cancer treatment if these agents decrease tumour blood flow and/or decrease tumour pH. One agent that has been studied extensively for this purpose is glucose. The objective of this paper is to review the results on the effect of hyperglycaemia on normal and tumour tissue blood flow and pH and its role in hyperthermia. After a brief discussion of the role of tumour pH and blood flow in hyperthermia treatment, data available in the literature on the effect of hyperglycaemia on normal and tumour tissue blood flow and pH are reviewed. Finally, the role of hyperglycaemia in hyperthermia treatment is discussed, and various studies involving the combined treatment are summarized. Key unanswered questions and directions for future research are pointed out.

Entities:  

Mesh:

Year:  1988        PMID: 3290346     DOI: 10.3109/02656738809051100

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  13 in total

1.  Nigericin enhances mafosfamide cytotoxicity at low extracellular pH.

Authors:  E Jähde; K H Glüsenkamp; M F Rajewsky
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Induced hyperglycemia and tumor chemotherapy: experimental and clinical studies.

Authors:  S P Osinsky; G V Evtushenko; E A Annin; L N Bubnovskaja
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

3.  Laser Doppler flux and tissue oxygenation of experimental tumours upon local hyperthermia and/or hyperglycaemia.

Authors:  W K Mayer; M Stohrer; W Krüger; P Vaupel
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

4.  Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy.

Authors:  Dhaval K Shah; Beom Soo Shin; Jean Veith; Karoly Tóth; Ralph J Bernacki; Joseph P Balthasar
Journal:  J Pharmacol Exp Ther       Date:  2009-02-20       Impact factor: 4.030

Review 5.  1995 Whitaker Lecture: delivery of molecules, particles, and cells to solid tumors.

Authors:  R K Jain
Journal:  Ann Biomed Eng       Date:  1996 Jul-Aug       Impact factor: 3.934

Review 6.  Vascular and interstitial barriers to delivery of therapeutic agents in tumors.

Authors:  R K Jain
Journal:  Cancer Metastasis Rev       Date:  1990-11       Impact factor: 9.264

7.  Microregional distributions of glucose, lactate, ATP and tissue pH in experimental tumours upon local hyperthermia and/or hyperglycaemia.

Authors:  C Schaefer; W K Mayer; W Krüger; P Vaupel
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

8.  Delivery of molecular and cellular medicine to solid tumors.

Authors:  Rakesh K Jain
Journal:  Adv Drug Deliv Rev       Date:  2012-12-01       Impact factor: 15.470

9.  Acute changes of systemic parameters in tumour-bearing rats, and of tumour glucose, lactate, and ATP levels upon local hyperthermia and/or hyperglycaemia.

Authors:  W Krüger; W K Mayer; C Schaefer; M Stohrer; P Vaupel
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

10.  Magnetic Resonance Imaging and Spectroscopy: Application to Experimental Neuro-Oncology.

Authors:  Brian D Ross; Thomas L Chenevert; Boklye Kim; Oded Ben-Yoseph
Journal:  Q Magn Reson Biol Med       Date:  1994
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.